Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Veeva Systems and Sarah Cannon Research Institute (SCRI) announced a strategic collaboration to drive speed and efficiency in oncology clinical trials across SCRI's more than 200 research site locations.
read more
Veeda Lifesciences has announced an investment in Mango Sciences, a Boston-based healthcare AI and data company. Through this investment, Veeda intends to leverage AI capabilities to enhance the speed, efficiency, and quality of Clinical Trials ...
read more
Thursday, January 02, 2025
Veeda Group has unveiled a new logo and brand identity - Veeda Lifesciences. The new brand name reflects the evolution from a generics-focused Contract Research Organization (CRO) to a drug development services enterprise for different modalities of ...
read more
Veeda Clinical Research announced their clinical (Shivalik, Ahmedabad) and Bioanalytical facilities (Insignia, Ahmedabad) have successfully completed the third inspection by NPRA.
read more
Monday, November 05, 2018
Veeda Clinical Research announce that the Shivalik, Insignia and Vedant facility had successfully completed fifth Inspection by WHO without any critical observations.
read more
Veeda Clinical Research Limited announced that it has acquired Heads, a privately held European CRO, which specializes in conducting clinical trials in oncology. Established in 2010, Heads has operational presence in 25 multiple strategically ...
read more
Friday, September 18, 2020
Vectura has signed an agreement with Monash University’s Institute of Pharmaceutical Sciences to develop inhaled oxytocin to prevent postpartum haemorrhage.
read more
Vectura Group plc announced it has signed an agreement with Incannex Healthcare Limited, an Australian cannabinoid medicines development company, to provide pre-clinical development services for IHL-216A, Incannex’s proprietary inhaled drug product ...
read more
Wednesday, December 09, 2020
Vectura has signed a global license and development agreement with Kinaset for VR588, a preclinical novel inhaled pan-JAK inhibitor for prevention and treatment of severe asthma.
read more
Vectura Group announced an expansion of its dry powder inhaler (DPI) development and manufacturing capabilities at its facility in Chippenham, U.K.
read more
Monday, December 21, 2020
Vectura Group announced an expansion of its capabilities to handle and develop HPAPIs at its facility in Chippenham, U.K.
read more
Vectura announced three appointments to its business development team.
read more
Friday, December 18, 2020
Vectura has announced its partner Hikma has launched its generic version of GlaxoSmithKline’s Advair Diskus, 100mcg/50mcg and 250mcg/50mcg doses, in the US.
read more
Vectura Group announced Mark Bridgewater has been appointed as Chief Commercial Officer, a newly-created role focused in the Company.
read more
Monday, February 10, 2020
Vectura Group announced Sharon Johnson has been appointed to the position of Executive Vice President for Delivery Management, a newly-created leadership role.
read more